Generation, characterization, and validation of marmoset models of alzheimer's disease

Active Cooperative Agreement Awarded Last action

Award ID
U19AG074866
Recipient
Awarding agency
Obligated
$65,017,335

Award facts

Assistance listing
93.866 Aging Research
Completion date 83% complete
Place of performance
Pittsburgh, PA 15213, USA

Award details come from USAspending.gov.

Description

Abstract
Overall alzheimer's disease (ad) is a devastating neurodegenerative disorder affecting nearly 6 million americans and is expected to increase over the next several years. Our limited understanding of the mechanisms that trigger the emergence of ad has contributed to the lack of interventions that stop, prevent, or fully treat this disease. We propose to establish the marmoset as the first primate-specific model to reveal the earliest cellular and molecular events of ad processes and allow charting ad progression from its inception. To do so, we will draw from a self-sufficient and large colony of research marmosets with dedicated veterinary and husbandry teams, state-of-the-art in vivo neuroimaging and molecular assays, and a multidisciplinary team of experts in aging biology, ad genetics and genomics, animal model development and characterization, behavioral and cognitive phenotyping, and marmoset gene-editing technologies. Our proposal's overarching goals are to develop marmoset models of early-onset ad (EOAD) and late-onset ad (LOAD) to enable the investigation of the underlying cellular and molecular root causes of the pathogenesis and progression of ad and support future translational studies. We believe that the simultaneous assessment of genetic, molecular, functional, behavioral, and pathological phenotypes in marmosets will provide translatable knowledge of the origins and progression of ad in human populations. Furthermore, we posit that the comprehensive study of gene-edited marmoset models of ad from neurodevelopment through aging will identify emerging phenotypes that precede frank neuropathology. Our proposal consists of 3 integrated research projects that aim to: (1) conduct characterization and validation of PSEN1 mutations in marmosets as a model for the study of EOAD, and investigate early life molecular determinants of ad disease pathogenesis associated with genetic risk for EOAD; (2) identify and enhance LOAD-related signatures in outbred and genetically-engineered marmosets; and (3) conduct a comparative multimodal phenotypic characterization of marmoset models of ad. These projects will be supported by 5 research cores focused on project administration, bioinformatics, genetic engineering, multimodal disease characterization, and veterinary and colony management. These supporting cores will integrate marmoset and human genomic signatures and provide data dissemination and resources to the greater research community as part of our commitment to open science, generate novel gene-edited marmoset models of ad, develop optimized protocols for studying disease onset and trajectory in line with clinical protocols, evaluate therapeutic strategies, and provide specialized animal care and support, respectively, allowing complete characterization of the marmoset models. At the conclusion of this project, we will have genetically engineered three ad risk variants into marmoset models, established a disease characterization pipeline for comprehensive phenotyping, and shared these resources with the greater research community.

Transactions

Action Obligated Date
Amendment $8,268,849
Amendment $0
Amendment $0
Amendment $620,720
Amendment $620,720
Amendment $524,539
Amendment $524,539
Amendment $7,003,124
Amendment $7,003,124
Amendment $376,991
Amendment $0
Amendment U19 marmo-ad supplement: resources for marmoset fibroblasts conversion pipeline $6,287,895
Amendment $0
Amendment U19 marmo-ad supplement: resources for marmoset fibroblasts conversion pipeline $0
Amendment $6,959,463
Amendment $6,959,463
Amendment $777,470
Amendment $777,470
Amendment $777,470
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $5,845,166
Amendment $5,845,166
Original award $5,845,166
Show all 27

Subawards

Subrecipient Amount Awarded
Sage Bionetworks Generation, Characterization, and Validation of Marmoset Models of Alzheimer's Disease $701,008
University Of California Santa Cruz $133,540
Emory University $312,487
Subrecipient not on record $35,409
Subrecipient not on record $396,597
Subrecipient not on record $554,888
Sage Bionetworks $180,504
Jackson Laboratory $458,990
Jackson Laboratory $396,596
Jackson Laboratory $35,408
Emory University $242,375
University Of California Santa Cruz $66,770
Sage Bionetworks $185,919
Jackson Laboratory $36,825
Jackson Laboratory $511,554
Jackson Laboratory $412,460
Emory University $218,697
University Of California Santa Cruz $68,773
University Of California Santa Cruz $66,770
Sage Bionetworks Generation, Characterization, and Validation of Marmoset Models of Alzheimer's Disease (BDIC CORE) $155,004
Show all 20

Quick answers

Who received award U19AG074866?

U19AG074866 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Institute on Aging (National Institutes of Health) on September 1, 2022.

How much is award U19AG074866 worth?

$65,017,335 has been obligated on U19AG074866.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award